Keurig Dr Pepper Inc. Common Stock vs Medpace Holdings Inc — how do they compare? Keurig Dr Pepper Inc. Common Stock trades at $31.76 (market cap $42.54B), while Medpace Holdings Inc trades at $612.05 (market cap $16.82B). The key difference: Keurig Dr Pepper Inc. Common Stock is far larger — about 2.5× Medpace Holdings Inc's market cap, and Keurig Dr Pepper Inc. Common Stock pays a 2.94% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Keurig Dr Pepper Inc. Common Stock for 1 Days and Medpace Holdings Inc for 14 Days on average.
| KDP | MEDP | |
|---|---|---|
Market Cap | $42.54B | $16.82B |
Volume | 14,530,234 | 223,093 |
Sector | Consumer Staples | Health |
52-Week High | $33.50 | $630.19 |
52-Week Low | $25.31 | $393.42 |
Typical Hold Time | 1 Days | 14 Days |
Enterprise Value | $71.00B | $16.44B |
Dividend Yield | 2.94% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Keurig Dr Pepper produces and distributes coffee, soft drinks, juices, and other beverages. It also operates the Keurig single-serve coffee system.
Read more on KDP →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →